

10/587758

CASE 33648-US-PCT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF

LEIGH ZAWEL

INTERNATIONAL APPLICATION NO: PCT/EP2005/001180

FILED: 4 FEBRUARY 2005

U.S. APPLICATION NO: Not Yet Assigned

35 USC §371 DATE:

FOR: COMBINATION OF (A) A DNA TOPOISOMERASE INHIBITOR AND
(B) AN IAP INHIBITOR

MS: Amendment

Commissioner for Patents

PO Box 1450

Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is being filed within three months of the date of entry of the national stage as set forth in 37 C.F.R. §1.491 of the international application. Therefore, no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.

In accordance with 37 C.F.R. §1.56, applicant wishes to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

The listed references were cited in the international stage search report. Since these references are of record in the instant PCT application PCT/EP2005/001180, copies are not enclosed herewith.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /I.B./


10/587758

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

AP20 Rec'd PCT/PTO 28 JUL 2006

Respectfully submitted,

Novartis
Corporate Intellectual Property
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(862) 778-7898


Lydia T. McNally
Attorney for Applicant
Reg. No. 36,214

Date: July 28, 2006

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Sheet 1 of 1
ATTY. DOCKET NO. 10/587758
33648-US-PCT
APPLICATION NO.
Not Yet Known
APPLICANT
Leigh ZAWEL
FILING DATE
Herewith

Group

AP20 Rec'd PCT/70 18 JUL 2006

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA	2003/0190659	10/9/03	Lacasse et al.			
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AM	03/045974A	6/5/03	WO			<input type="checkbox"/>	<input type="checkbox"/>
	AN	2004/005248A	1/15/04	WO			<input type="checkbox"/>	<input type="checkbox"/>
	AO						<input type="checkbox"/>	<input type="checkbox"/>
	AP						<input type="checkbox"/>	<input type="checkbox"/>
	AQ						<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	AR	Arnt et al., "Synthetic Smac/DIABLO Peptides Enhance the Effects of Chemotherapeutic Agents by Binding XIAP and cIAP1 in Situ," The Journal of Biological Chemistry, Vol. 277(46), pp. 44236-44243 (2002)
	AS	Fang et al., "CGP57148B (STI-571) induces differentiation and apoptosis and sensitizes Bcr-Abl-positive human leukemia cells to apoptosis due to antileukemic drugs," Blood, Vol. 96(6), pp. 2246 (2000)
	AT	Hu Y. et al., Proceedings of the American Association for Cancer Research, Vol. 43, p. 576 (March 2002)

EXAMINER

/Ibrahim Boril/

DATE CONSIDERED

08/26/2011

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /I.B./